Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Open Access
- 29 May 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 373 (9677), 1780-1788
- https://doi.org/10.1016/s0140-6736(09)60698-x
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic SyndromeDiabetes Care, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibitionProceedings of the National Academy of Sciences of the United States of America, 2008
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 2007
- Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVECBiochemical and Biophysical Research Communications, 2006
- Lower extremity minor amputations: The roles of diabetes mellitus and timing of revascularizationJournal of Vascular Surgery, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- No Adjustments Are Needed for Multiple ComparisonsEpidemiology, 1990